Victory Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Victory Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$7.84M	Buy	89,007 +692	+0.8%	+$71.8K	﹤0.01%	1211
2026 Q2	$8.61M	Buy	88,315 +72,653	+464%	+$6.35M	﹤0.01%	1185
2026 Q1	$1.31M	Buy	15,662 +872	+6%	+$50.5K	﹤0.01%	1731
2025 Q4	$609K	Buy	+14,790	New	+$573K	﹤0.01%	1985
2020 Q2	–	Sell	-221	Closed	-$22K	–	2720
2020 Q1	$22K	Buy	+221	New	+$41K	﹤0.01%	2810
2019 Q4	–	Sell	-187	Closed	-$31K	–	2811
2019 Q3	$31K	Buy	+187	New	+$35.5K	﹤0.01%	2890

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Fisher Asset Management Camas, Washington $348B AUM 26.9% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Victory Capital Management's DNTH Position: Q3 2026 in Review

Victory Capital Management increased its Dianthus Therapeutics (DNTH) stake by 0.78% in Q3 2026, buying an estimated $71.8K and bringing the position to 89,007 shares worth $7.84M. The position accounts for ﹤0.01% of the portfolio, ranked #1211.

Victory Capital Management first reported a position in DNTH in Q3 2019 and has held it in 6 quarters since. The position peaked at $8.61M in Q2 2026. 109 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

Victory Capital Management held 89,007 shares of Dianthus Therapeutics worth $7.84M as of Q3 2026.
Victory Capital Management bought 692 Dianthus Therapeutics shares in Q3 2026, an estimated $71.8K.
Dianthus Therapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q3 2026, its #1211 holding.
Victory Capital Management first reported a position in Dianthus Therapeutics in Q3 2019 and has held it in 6 quarters since.
Victory Capital Management's Dianthus Therapeutics position peaked at $8.61M in Q2 2026.
109 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Victory Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.